Comparison Overview

Hengrui Pharma Co.,Ltd

VS

Dr. Reddy's Laboratories

Hengrui Pharma Co.,Ltd

Pudong New Area, Shanghai, China, No. 1288, Haike Road, Shanghai, Shanghai, CN, None
Last Update: 2025-11-20
View Profile
Between 800 and 849
https://www.hengrui.com/

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma’s therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 19 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 3,527
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TS, IN, 500034
Last Update: 2025-11-20
Between 750 and 799
http://www.drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com.  Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages.  Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 30,765
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/jiangsu-hengrui-pharmaceuticals.jpeg
Hengrui Pharma Co.,Ltd
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/dr--reddys-laboratories.jpeg
Dr. Reddy's Laboratories
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Hengrui Pharma Co.,Ltd
100%
Compliance Rate
0/4 Standards Verified
Dr. Reddy's Laboratories
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hengrui Pharma Co.,Ltd in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Dr. Reddy's Laboratories in 2025.

Incident History — Hengrui Pharma Co.,Ltd (X = Date, Y = Severity)

Hengrui Pharma Co.,Ltd cyber incidents detection timeline including parent company and subsidiaries

Incident History — Dr. Reddy's Laboratories (X = Date, Y = Severity)

Dr. Reddy's Laboratories cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/jiangsu-hengrui-pharmaceuticals.jpeg
Hengrui Pharma Co.,Ltd
Incidents

No Incident

https://images.rankiteo.com/companyimages/dr--reddys-laboratories.jpeg
Dr. Reddy's Laboratories
Incidents

No Incident

FAQ

Hengrui Pharma Co.,Ltd company demonstrates a stronger AI Cybersecurity Score compared to Dr. Reddy's Laboratories company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Dr. Reddy's Laboratories company has disclosed a higher number of cyber incidents compared to Hengrui Pharma Co.,Ltd company.

In the current year, Dr. Reddy's Laboratories company and Hengrui Pharma Co.,Ltd company have not reported any cyber incidents.

Neither Dr. Reddy's Laboratories company nor Hengrui Pharma Co.,Ltd company has reported experiencing a ransomware attack publicly.

Neither Dr. Reddy's Laboratories company nor Hengrui Pharma Co.,Ltd company has reported experiencing a data breach publicly.

Neither Dr. Reddy's Laboratories company nor Hengrui Pharma Co.,Ltd company has reported experiencing targeted cyberattacks publicly.

Neither Hengrui Pharma Co.,Ltd company nor Dr. Reddy's Laboratories company has reported experiencing or disclosing vulnerabilities publicly.

Neither Hengrui Pharma Co.,Ltd nor Dr. Reddy's Laboratories holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Hengrui Pharma Co.,Ltd company nor Dr. Reddy's Laboratories company has publicly disclosed detailed information about the number of their subsidiaries.

Dr. Reddy's Laboratories company employs more people globally than Hengrui Pharma Co.,Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Hengrui Pharma Co.,Ltd nor Dr. Reddy's Laboratories holds SOC 2 Type 1 certification.

Neither Hengrui Pharma Co.,Ltd nor Dr. Reddy's Laboratories holds SOC 2 Type 2 certification.

Neither Hengrui Pharma Co.,Ltd nor Dr. Reddy's Laboratories holds ISO 27001 certification.

Neither Hengrui Pharma Co.,Ltd nor Dr. Reddy's Laboratories holds PCI DSS certification.

Neither Hengrui Pharma Co.,Ltd nor Dr. Reddy's Laboratories holds HIPAA certification.

Neither Hengrui Pharma Co.,Ltd nor Dr. Reddy's Laboratories holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Angular is a development platform for building mobile and desktop web applications using TypeScript/JavaScript and other languages. Prior to versions 19.2.16, 20.3.14, and 21.0.1, there is a XSRF token leakage via protocol-relative URLs in angular HTTP clients. The vulnerability is a Credential Leak by App Logic that leads to the unauthorized disclosure of the Cross-Site Request Forgery (XSRF) token to an attacker-controlled domain. Angular's HttpClient has a built-in XSRF protection mechanism that works by checking if a request URL starts with a protocol (http:// or https://) to determine if it is cross-origin. If the URL starts with protocol-relative URL (//), it is incorrectly treated as a same-origin request, and the XSRF token is automatically added to the X-XSRF-TOKEN header. This issue has been patched in versions 19.2.16, 20.3.14, and 21.0.1. A workaround for this issue involves avoiding using protocol-relative URLs (URLs starting with //) in HttpClient requests. All backend communication URLs should be hardcoded as relative paths (starting with a single /) or fully qualified, trusted absolute URLs.

Published
Date
2025-11-26
Updated
Date
2025-11-26
Risk Information
cvss4
Base: 7.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Uncontrolled Recursion vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft deep ASN.1 structures that trigger unbounded recursive parsing. This leads to a Denial-of-Service (DoS) via stack exhaustion when parsing untrusted DER inputs. This issue has been patched in version 1.3.2.

Published
Date
2025-11-26
Updated
Date
2025-11-26
Risk Information
cvss4
Base: 8.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Integer Overflow vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft ASN.1 structures containing OIDs with oversized arcs. These arcs may be decoded as smaller, trusted OIDs due to 32-bit bitwise truncation, enabling the bypass of downstream OID-based security decisions. This issue has been patched in version 1.3.2.

Published
Date
2025-11-26
Updated
Date
2025-11-26
Risk Information
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. Prior to versions 7.0.13 and 8.0.2, working with large buffers in Lua scripts can lead to a stack overflow. Users of Lua rules and output scripts may be affected when working with large buffers. This includes a rule passing a large buffer to a Lua script. This issue has been patched in versions 7.0.13 and 8.0.2. A workaround for this issue involves disabling Lua rules and output scripts, or making sure limits, such as stream.depth.reassembly and HTTP response body limits (response-body-limit), are set to less than half the stack size.

Published
Date
2025-11-26
Updated
Date
2025-11-26
Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
References
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. In versions from 8.0.0 to before 8.0.2, a NULL dereference can occur when the entropy keyword is used in conjunction with base64_data. This issue has been patched in version 8.0.2. A workaround involves disabling rules that use entropy in conjunction with base64_data.

Published
Date
2025-11-26
Updated
Date
2025-11-26
Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
References